The Two-Decade Delay in Lyme-Disease Vaccines

Initially halted by public fears, a preventive treatment could be here in two years.
By Sue Halpern
Tweezers point to two very small ticks in a zipped plastic bag.
The ticks that carry the bacteria responsible for Lyme disease are tiny, their bites are painless, and they don’t always trigger a telltale bull’s-eye-shaped rash.   Photograph by Edwin Remsburg / Getty

In May, an article with the unprepossessing title “Detecting Borrelia Spirochetes: A Case Study with Validation Among Autopsy Specimens” was published in the medical journal Frontiers in Neurology. The deceased person in question was a sixty-nine-year-old woman who suffered from severe cognitive impairment. Fifteen years before her death she had been treated for Lyme disease, the most prevalent tick-borne illness in the United States, and was thought to have fully recovered. Yet, when her brain and spinal-cord tissue were examined, researchers found intact Borrelia spirochetes, the bacteria responsible for Lyme. If the woman’s cognitive decline did result from Lyme disease—which the paper suggested was a strong possibility—then it was further evidence that the illness could persist and wreak havoc long after a tick bite, and long after treatment.

The standard therapy for Lyme disease is a course of antibiotics, typically doxycycline. Ideally, the medication should be taken within a few days of infection, but it’s tricky. The ticks that carry the bacteria are about the size of a poppy seed, their bites are painless, and not everyone gets a telltale bull’s-eye-shaped rash at the site of the bite. Many people don’t know they’ve been infected until they become symptomatic with joint pain, fever, body aches, chills, heart palpitations, myocarditis, and brain fog, at which point the antibiotics may be ineffective. Of the estimated half a million people who get Lyme disease each year in the United States, around ten to twenty per cent might fall into this category. But, as the dead woman’s brain showed, sometimes, even when the antibiotic is administered at the right time, it’s insufficient. A more effective strategy would be to impede transmission before the bacteria have a chance to enter the bloodstream. And that, too, has been tricky—but may be about to change.

There used to be a Lyme vaccine—and then, in a rare occurrence in modern medicine, it disappeared.

(See link for article)

________________________

**Comment**

A few points for consideration:

  1. While GSK abandoned LYMErix, citing poor sales, the Lyme community knows the real story – it caused patients to develop Lyme-like symptoms and other severe adverse events – the very thing they were hoping to avoid.
  2. LYMErix was given “permissive” recommendation by the CDC (the injection was only advised for those ‘at risk’, not the whole population). This designation allowed those suffering with adverse reactions to sue the manufacturer, which they did.
  3. The author states the “unlikely villain” in this story are suffering patients. Wow.
  4. The “scientists” the author talked with (likely the ones creating the vaccine) told her that “people came to believe it caused arthritis).  The belief issue is a common refrain in Lyme-land.  Can you blame patients for being highly skeptical when they aren’t believed?
  5. A half-dozen class-action lawsuits against GSK, were consolidated into a single suit which claimed that the company had withheld evidence of the Lyme vaccine’s dangers. BTW: it’s been done before, and now due to tyrannical censorship, this information is being scrubbed from the internet. There is also a long, sordid history with a group of scientists within the CDC exposing interagency corruption. There’s also the following issues: lack of research ethics, manipulating & weaponizing data, including the glaring lack of vaccine safety studies, conflicts of interest including a revolving door between public health ‘authorities’ and Big Pharma, infighting, and vaccine injury denial.
  6. The article insists that data show that “the arthritis incidence in the patients receiving Lyme vaccine occurred at the same rate as the background in unvaccinated individuals. . . .and that the FDA found no link between the vaccine and harm. If there’s one thing we should have learned this year, it’s that data can be manipulated to say whatever you want it to say. Flawed study design is rampant, but is used to control the narrative.
  7. University researchers depend upon government money doled out by none other than the dishonorable and corrupt Dr. Fauci, head of NIAD for 7 presidencies, who makes more money than the President of the United States.  John Aucott, realizing his funding comes from a bully who will pull his funding or discredit him if he speaks freely must straddle the fence and state that people have reactions after every vaccine and that occasionally there is a rare side-effect that can never be discerned between someone destined to have it or caused by the vaccine. PC at its best.  Call me crazy, but I tend to believe thousands of patients who suddenly developed Lyme-like symptoms after a vaccine, that were fine previously.
  8. Dr. Mark Klempner calls LYMErix’s removal a “tragedy.” His new lucrative jab called Lyme PrEP is now in Phase 1 trials. Please know the backstory on Klempner. He claims this new shot isn’t a “vaccine;” however, according to this,  OspA is still in it. Here’s what Dr. Stricker has to say about OspA:Another Lyme OspA Vaccine Whitewash

    The meta-analysis by Zhao and colleagues comes to the conclusion that “the OspA vaccine against Lyme disease is safe and its immunogenicity and efficacy have been verified.” The authors arrive at this sunny conclusion by excluding 99.6% of published articles that demonstrate potential problems with the OspA vaccine. Furthermore, the authors ignore peer-reviewed studies, FDA regulatory meetings and legal proceedings that point to major problems with OspA vaccine safety (1-3). This whitewash bodes ill for future Lyme vaccine candidates because it fosters disregard for vaccine safety among Lyme vaccine manufacturers and mistrust among potential Lyme vaccinees.

  9. Sam Telford, another member of The Cabal, laments it didn’t help that at the same time a rotavirus vaccine for children was demonstrated to actually do harm, adding to the growing anti-vaccine sentiment. Do these people have a hearts in their bodies at all?
  10. French pharmaceutical company Valneva joined up with Pfizer (a company which has been fined over 3.5 billion for safety violations, false medical claims, corruption, bribery and has demanded countries put up sovereign assets, bank reserves, military bases and embassy buildings as collateral for expected lawsuits from COVID shots) to develop a vaccine (currently in a 3rd phase II trial) that is reminiscent of LYMErix.
  11.  The author of the article doubts that the vocal anti-vaccine sentiment around the various covid “vaccines” will affect these new Lyme-disease pharmaceuticals (which still have OspA in them), as they claim some are not traditional vaccines. She also feels that the high Lyme disease numbers due to ticks expanding their range will also make people take the jab.
  12. She then compares COVID, which she states is a highly transmissible disease threatening public health to Lyme which she states is not communicable.
  13. Now Aucott is “cloning a bunch of proteins in tick saliva” to replicate tick resistance, but he’s also an adviser to Tarsus Pharmaceuticals, a biopharmaceutical company which is authorized by the F.D.A. to develop an oral preventative in humans using lotilaner, the active ingredient in Credelio, a veterinary medication prescribed for dogs and cats to prevent fleas and ticks which is targeted to the parasite’s nervous system but supposedly doesn’t have any effect on mammals.
  14. Since it’s going to be a couple years before any of these lucrative drugs come to market The Cabal recommends taking normal precautions when going outdoors, and to not be afraid.